Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Coronary Artery Disease II: Pathophysiology
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Coronary Artery Disease III: Clinical Manifestations
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 2, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
Published on: August 24, 2013
Ani Manichaikul1, Stephen S Rich2, Heather Perry3
1Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, United States of America; Division of Biostatistics and Epidemiology, Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, United States of America.
The ID3 SNP rs11574 risk allele is linked to coronary artery pathology, including coronary artery calcium and atheroma burden. This finding reinforces the association between this genetic marker and cardiovascular disease progression in diverse populations.
09:37A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: